e2f7 Antibody

What is E2F7 and why is it significant in cell cycle research?

E2F7 is a distinctive member of the E2F transcription factor family that contains two DNA binding domains, unlike other E2F proteins which contain only one. It functions primarily as a transcriptional repressor of E2F-regulated genes that are crucial for cell cycle progression. E2F7 is significant in cell cycle research because it represents a unique mechanism of E2F-dependent transcriptional regulation, binding to DNA independently of DP proteins and repressing a specific subset of E2F target genes involved in the G1/S transition . Research has shown that E2F7 primarily occupies promoters of genes like E2F1 and CDC6 during S phase, suggesting its role in the proper timing of early E2F target gene expression .

How does E2F7 differ structurally and functionally from other E2F family members?

E2F7 differs from other E2F family members in several important ways:

• Dual DNA binding domains: E2F7 contains two conserved DNA binding domains (DB1 and DB2), both of which are required for functional DNA binding .

• DP-independent mechanism: Unlike classic E2Fs that require dimerization with DP proteins for DNA binding, E2F7 binds to E2F consensus sites through the formation of intramolecular homodimers .

• Repressor activity: E2F7 functions exclusively as a repressor, unlike other E2F members that can act as either activators or repressors depending on context .

• Target specificity: E2F7 selectively represses a subset of E2F-responsive genes (E2F1, CDC6, CCNE1) but not others (CCNA2, CDC2), indicating a more specialized regulatory role .

What are the common applications for E2F7 antibodies in basic research?

E2F7 antibodies are valuable tools in basic research with several key applications:

• Western blotting: For detecting E2F7 protein expression levels in various cell types and conditions

• Immunoprecipitation: For studying protein-protein interactions and complex formation (E2F7 can form homodimers)

• Chromatin Immunoprecipitation (ChIP): For identifying genomic regions bound by E2F7 in vivo, as demonstrated in studies showing E2F7 occupancy on specific promoters

• Immunofluorescence: For examining subcellular localization of E2F7

• Flow cytometry: For correlating E2F7 expression with cell cycle phases

• EMSA (Electrophoretic Mobility Shift Assay): For analyzing E2F7 binding to DNA consensus sequences in vitro

What are the optimal protocols for using E2F7 antibodies in Chromatin Immunoprecipitation (ChIP) assays?

For optimal ChIP assays with E2F7 antibodies, researchers should consider the following methodological approach:

• Cross-linking: Perform formaldehyde cross-linking (1% for 10 minutes at room temperature) to preserve protein-DNA interactions

• Sonication: Optimize sonication conditions to obtain DNA fragments between 200-500 bp

• Antibody selection: Use ChIP-validated E2F7 antibodies that recognize epitopes not affected by formaldehyde treatment

• Controls: Include:

  • Input DNA (pre-immunoprecipitation)

  • Negative control (non-specific IgG)

  • Positive control (antibody against known interacting protein)

  • Non-target gene control (e.g., β-actin promoter used in published studies)

• Washing conditions: Use stringent washing conditions to reduce background

• Analysis: Analyze using qPCR with primers targeting known E2F binding sites

Based on published research, E2F7 ChIP assays have successfully identified binding to E2F1 and CDC6 promoters during S phase, while showing minimal enrichment at CCNA2 and CDC2 promoters .

How can researchers optimize western blot conditions for detecting E2F7?

Optimizing western blot conditions for E2F7 detection requires:

• Sample preparation:

  • Use RIPA or E1A lysis buffer with protease inhibitors

  • Include phosphatase inhibitors if studying post-translational modifications

  • Maintain cold temperatures during extraction

• Gel electrophoresis:

  • Use 8% SDS-PAGE gels to properly resolve E2F7's molecular weight

  • Load appropriate protein amount (typically 30-50 μg total protein)

• Transfer conditions:

  • Wet transfer at 100V for 90 minutes or overnight transfer at 30V

  • Use PVDF membrane (preferred over nitrocellulose for detection of transcription factors)

• Antibody incubation:

  • Block with 5% non-fat milk or BSA in TBST

  • Incubate with primary antibody at 1:1000 dilution overnight at 4°C

  • Use antibodies that recognize epitopes common to both E2F7a (728 amino acids) and E2F7b (911 amino acids) isoforms unless studying isoform-specific expression

• Detection:

  • Secondary antibody at 1:5000 for 1 hour at room temperature

  • Include positive controls (cells transfected with E2F7 expression vectors)

What are reliable validation methods to ensure E2F7 antibody specificity?

Reliable validation methods for E2F7 antibody specificity include:

• Genetic validation:

  • Testing in E2F7 knockout/knockdown models (siRNA or CRISPR)

  • Overexpression systems with tagged E2F7 constructs

• Peptide competition assays:

  • Pre-incubation of antibody with immunizing peptide should abolish signal

• Multiple antibody validation:

  • Use antibodies targeting different epitopes of E2F7

  • Compare antibodies from different vendors/sources

• Cross-reactivity testing:

  • Test against related E2F family members, especially newer members like E2F8

• Application-specific validation:

  • For ChIP: DNA binding mutants (E2F7-E146, E2F7ΔDB1, E2F7ΔDB2) should show reduced or no signal

  • For immunoprecipitation: Validate by mass spectrometry of immunoprecipitated proteins

• Isoform specificity:

  • Verify detection of both E2F7a and E2F7b isoforms or use isoform-specific antibodies when needed

How can E2F7 antibodies be used to investigate E2F7's role in the negative feedback regulation of the cell cycle?

E2F7 antibodies can be instrumental in investigating the negative feedback loop between E2F1 and E2F7:

• ChIP-sequencing approaches:

  • Map genome-wide binding sites of E2F7 across cell cycle phases

  • Compare with E2F1 binding patterns to identify targets under reciprocal regulation

  • Overlay with histone modification data to understand chromatin context

• Synchronized cell systems:

  • Perform time-course experiments in synchronized cells

  • Use E2F7 antibodies for ChIP and western blot at different time points

  • Correlate E2F7 binding with target gene expression using RT-qPCR

• Protein complex identification:

  • Use E2F7 antibodies for co-immunoprecipitation followed by mass spectrometry

  • Identify cell cycle-dependent interaction partners

• Combined approaches:

  • ChIP-reChIP to investigate co-occupancy or sequential binding of E2F1 and E2F7

  • Integrate with RNA-seq data after E2F7 depletion/overexpression

Research has demonstrated that E2F1 stimulates E2F7 expression while E2F7 represses E2F1, creating a negative feedback mechanism crucial for proper timing of E2F target gene expression during the cell cycle . This feedback loop can be monitored using antibodies in time-course experiments.

What methodologies are recommended for studying E2F7 binding dynamics to different promoters?

For studying E2F7 binding dynamics to different promoters, researchers should consider:

• Cell cycle-specific ChIP:

  • Synchronize cells at different cell cycle phases

  • Perform ChIP with E2F7 antibodies at each time point

  • Analyze binding to different target promoters by qPCR

• Live-cell imaging approaches:

  • Generate cell lines expressing fluorescently tagged E2F7

  • Use fluorescence recovery after photobleaching (FRAP) to study binding kinetics

  • Validate findings with endogenous E2F7 using antibodies

• Sequential ChIP (ChIP-reChIP):

  • Analyze co-occupancy with other transcription factors or chromatin modifiers

  • First ChIP with E2F7 antibody followed by second ChIP with antibodies against other factors

• Promoter-specific analysis:

  • Focus on E2F1 and CDC6 promoters (known E2F7 targets)

  • Include CCNA2 and CDC2 promoters as negative controls

  • Design primers spanning different E2F binding sites within each promoter

Research has shown that E2F7 primarily occupies E2F1 and CDC6 promoters during S phase but shows minimal binding to CCNA2 and CDC2 promoters . This differential binding pattern suggests context-specific recruitment of E2F7 to certain E2F-responsive promoters.

How can researchers distinguish between the functions of E2F7a and E2F7b isoforms?

To distinguish between the functions of E2F7a (728 amino acids) and E2F7b (911 amino acids) isoforms:

• Isoform-specific detection:

  • Use antibodies targeting the unique C-terminal regions of each isoform

  • For western blotting, optimize conditions to resolve the size difference

  • Perform RT-qPCR with isoform-specific primers spanning the alternative splicing junction

• Expression analysis:

  • Quantify relative abundance of each isoform across different tissues and cell lines

  • Analyze expression patterns during cell cycle progression

  • Determine if isoforms are differentially regulated

• Functional studies:

  • Generate isoform-specific expression constructs

  • Perform isoform-specific knockdown using siRNAs targeting unique regions

  • Compare functional readouts (transcriptional repression, cell cycle effects)

• Binding partner identification:

  • Perform co-immunoprecipitation with isoform-specific antibodies

  • Identify unique interaction partners by mass spectrometry

What role does E2F7 play in cancer biology and how can antibodies help investigate this?

E2F7's potential role as a tumor suppressor can be investigated using antibodies:

• Expression analysis in tumor samples:

  • Immunohistochemistry (IHC) with E2F7 antibodies on tissue microarrays

  • Correlation with clinical outcomes and molecular subtypes

  • Comparison with normal tissue controls

• Mechanism investigations:

  • ChIP-seq in cancer cell lines to identify altered binding patterns

  • Co-immunoprecipitation to detect cancer-specific protein interactions

  • Analysis of post-translational modifications in cancer contexts

• Functional studies:

  • Monitor E2F7 expression/localization during oncogene-induced proliferation

  • Analyze effects of tumor suppressor gene inactivation on E2F7 function

  • Investigate relationship between E2F7 and cancer-associated E2F target genes (CCNE1)

E2F7 is located at chromosome 12q21, a region whose deletion is associated with poor prognosis in pancreatic cancer patients . The observation that E2F7 represses genes like CCNE1 (cyclin E1), which is overexpressed in several cancers, further supports its potential tumor suppressor function .

How can E2F7 antibodies be used to study the relationship between E2F7 and cellular stress responses?

To study E2F7's role in cellular stress responses:

• Stress-induced expression changes:

  • Western blot analysis of E2F7 protein levels after various stressors (DNA damage, oxidative stress, hypoxia)

  • Immunofluorescence to determine changes in subcellular localization under stress

• Chromatin binding under stress:

  • ChIP-seq to map stress-induced changes in E2F7 genomic binding

  • Focus on promoters of stress-response genes and DNA repair factors

  • Compare with E2F1 binding (known to respond to DNA damage)

• Post-translational modifications:

  • Immunoprecipitation followed by mass spectrometry to identify stress-induced modifications

  • Use phospho-specific antibodies if key modifications are identified

  • Monitor changes in protein stability and turnover

• Integration with other stress pathways:

  • Co-immunoprecipitation to identify interactions with stress-response proteins

  • ChIP-reChIP to detect co-occupancy with stress-activated transcription factors

While the provided search results don't directly address E2F7's role in stress responses, the functional overlap with E2F1 (which has established roles in DNA damage responses) suggests potential involvement in cellular stress pathways.

What methodological approaches can reveal the therapeutic potential of targeting E2F7 in disease models?

Methodological approaches to explore E2F7's therapeutic potential include:

• Disease model characterization:

  • IHC analysis of E2F7 expression in patient samples and disease models

  • Correlation with disease progression markers

  • Association with treatment response and patient outcomes

• Functional manipulation studies:

  • Overexpression or depletion of E2F7 in disease models

  • Monitor effects on disease-relevant phenotypes

  • Validate antibody usefulness for tracking manipulation success

• Small molecule screening:

  • Develop assays using E2F7 antibodies to detect compounds that modulate E2F7 levels/activity

  • Focus on compounds that restore normal E2F7 function in disease contexts

  • Use antibodies to validate target engagement in vivo

• Combination therapy approaches:

  • Investigate E2F7 status as a biomarker for response to cell cycle-targeting drugs

  • Study synergistic effects of modulating E2F7 alongside standard therapies

  • Use antibodies to monitor pathway activation/inhibition

Since E2F7 negatively regulates cell proliferation and its overexpression blocks S phase entry , therapeutic approaches might aim to enhance E2F7 activity in hyperproliferative diseases.

What are common pitfalls when working with E2F7 antibodies and how can they be addressed?

Common pitfalls when working with E2F7 antibodies include:

• Cross-reactivity with other E2F family members:

  • Solution: Validate antibody specificity against recombinant E2F proteins

  • Use E2F7 knockout/knockdown controls

  • Confirm with multiple antibodies targeting different epitopes

• Isoform detection issues:

  • Solution: Verify which isoform(s) the antibody detects (E2F7a vs. E2F7b)

  • Use isoform-specific antibodies when necessary

  • Optimize gel conditions to resolve the size difference between isoforms

• Low signal in ChIP experiments:

  • Solution: Optimize crosslinking conditions

  • Increase antibody amount or incubation time

  • Use more sensitive detection methods (qPCR instead of conventional PCR)

  • Focus on verified targets (E2F1, CDC6 promoters)

• Variability across cell types:

  • Solution: Optimize protocols for each cell type

  • Consider E2F7 expression levels in different cells

  • Adjust lysis conditions based on subcellular localization

• Epitope masking by protein interactions:

  • Solution: Test multiple antibodies recognizing different epitopes

  • Consider native vs. denaturing conditions depending on application

How should researchers interpret conflicting results from different E2F7 antibodies?

When faced with conflicting results from different E2F7 antibodies:

• Antibody validation:

  • Verify each antibody's validation status for the specific application

  • Check epitope locations and potential overlap with protein interaction domains

  • Consider lot-to-lot variations within the same antibody

• Experimental controls:

  • Include positive controls (E2F7 overexpression)

  • Include negative controls (E2F7 knockdown/knockout)

  • Test in multiple cell lines to rule out cell type-specific effects

• Protocol variations:

  • Test different fixation/lysis conditions

  • Modify blocking reagents to reduce non-specific binding

  • Adjust antibody concentrations and incubation conditions

• Data integration:

  • Give more weight to results confirmed by multiple techniques

  • Consider complementary approaches (e.g., tagged E2F7 expression)

  • Consult literature for consistent patterns across studies

• Report transparently:

  • Document all antibody details (vendor, catalog number, lot, dilution)

  • Note any discrepancies between antibodies in publications

  • Contact antibody manufacturers for technical support

What data reporting standards should be followed when publishing research using E2F7 antibodies?

Researchers should adhere to these reporting standards when publishing with E2F7 antibodies:

• Antibody identification:

  • Manufacturer and catalog number

  • Clone number for monoclonal antibodies

  • Lot number when relevant

  • RRID (Research Resource Identifier) when available

• Validation documentation:

  • Specificity tests performed

  • Links to validation data or references

  • Controls used to verify performance

• Experimental conditions:

  • Detailed protocols including:

    • Antibody concentration/dilution

    • Incubation conditions (time, temperature)

    • Blocking reagents

    • Detection methods

• Cell/tissue information:

  • Cell types/tissues tested

  • Growth/treatment conditions

  • Fixation/lysis methods

• Data presentation:

  • Include representative images of full blots/gels

  • Show molecular weight markers

  • Include positive and negative controls

  • Present quantification with appropriate statistical analysis

Following these standards ensures experimental reproducibility and facilitates comparison across studies.